Correlation found between change in IOP and conjunctival hyperaemia induced by latanoprost

Article

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study.

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study published in the Journal of Glaucoma.

Drs Hiroshi and Kaori Kobayashi, from Amagasaki Hospital, Hyogo and Osaka Red Cross Hospital, Osaka, Japan, respectively, examined 114 patients with open-angle glaucoma or ocular hypertension. Their aim was to determine any correlation between a short-term change in conjunctival hyperaemia severity and the IOP-reducing effect induced by latanoprost.

Of the 114 patients 56 were female and 58 were male and they had a mean age of 60.9±15 years. The primary outcome of the study was to determine the change in conjunctival hyperaemia grade at day 2 and the change in IOP at 6 months after commencing latanoprost treatment.

The mean IOP before latanoprost treatment was 22.5±3.8 mmHg and after 6 months it was 16.5±2.9 mmHg (P < 0.0001). Mean changes in conjunctival hyperaemia before and after 2 days of latanoprost treatment were 0.32±0.58 and 1.74±1.11, respectively (P < 0.0001). It was found that the mean change in IOP was greater in eyes with a higher hyperaemia grade change.

In conclusion, the researchers found a significant correlation between the change in IOP and the conjunctival hyperaemia severity after treatment with latanoprost.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.